Trial Profile
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Orvacabtagene autoleucel (Primary) ; Corticosteroids; Cyclophosphamide; Fludarabine; Steroids; Tocilizumab
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms EVOLVE
- Sponsors Juno Therapeutics
- 19 Oct 2023 Status changed from active, no longer recruiting to completed.
- 17 Jun 2021 Results (n=33) assessing clinical outcomes of a cohort from phase 1 portion in patients treated prophylactically with anakinra and non-anakinra prophylaxis group presented at the 26th Congress of the European Haematology Association
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology